Innovent Biologics set for biggest rise in 2 weeks on robust Q1 revenue growth

Innovent Biologics

30/04/2026 03:26

** Shares of Innovent Biologics 1801.HK rise 5.4% to HK$89.5 in a second session of gains, on course for the biggest one-day pct gain since April 15

** Stock hits the highest point since April 22; second-biggest pct gainer in the benchmark Hang Seng Index .HSI, which slips 0.7%

** Chinese innovative medicines producer says its total product revenue for the first quarter of 2026 jumped over 50% y/y to 3.8 bln yuan ($555.46 mln)

** "Looking ahead, continuous progression of our domestic business and global pipeline development will steadily propel Innovent towards becoming a global premier biopharmaceutical company" - co

** YTD, stock up 15.9%, Hang Seng Biotech Index .HSBIO up 3.9%

($1 = 6.8412 Chinese yuan)

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))